We can only speculate that our sodium butyrate concentration was inadequate to inhibit HDAC activity or that PBMCs from participants with poorly controlled T2DM have an impaired response to sodium butyrate treatment. The gene discussed is HDAC9; the disease is type 2 diabetes mellitus.